Society for immunotherapy of cancer (sitc) clinical practice guideline on immune checkpoint inhibitor-related adverse events

Julie R. Brahmer; Hamzah Abu-Sbeih; Paolo Antonio Ascierto; Jill Brufsky; Laura C. Cappelli; Frank B. Cortazar; David E. Gerber; Lamya Hamad; Eric Hansen; Douglas B. Johnson; Mario E. Lacouture; Gregory A. Masters; Jarushka Naidoo; Michele Nanni; Miguel Angel Perales; Igor Puzanov; Bianca D. Santomasso; Satish P. Shanbhag; Rajeev Sharma; Dimitra Skondra; Jeffrey A. Sosman; Michelle Turner; Marc S. Ernstoff

doi:10.1136/jitc-2021-002435

Society for immunotherapy of cancer (sitc) clinical practice guideline on immune checkpoint inhibitor-related adverse events

Julie R. Brahmer
, Hamzah Abu-Sbeih
, Paolo Antonio Ascierto
, Jill Brufsky
, Laura C. Cappelli
, Frank B. Cortazar
, David E. Gerber
, Lamya Hamad
, Eric Hansen
, Douglas B. Johnson
, Mario E. Lacouture
, Gregory A. Masters
, Jarushka Naidoo
, Michele Nanni
, Miguel Angel Perales
, Igor Puzanov
, Bianca D. Santomasso
, Satish P. Shanbhag
, Rajeev Sharma
, Dimitra Skondra

Jeffrey A. Sosman, Michelle Turner, Marc S. Ernstoff

Medicine

Johns Hopkins University
University of Missouri at Kansas City
IRCCS Istituto nazionale tumori Fondazione Giovanni Pascale - Napoli
University of Pittsburgh
Massachusetts General Hospital
New York Nephrology Vasculitis and Glomerular Center
University of Texas Southwestern Medical Center
Roswell Park Cancer Institute
Vanderbilt University
Memorial Sloan-Kettering Cancer Center
Christiana Care Health System
Royal College of Surgeons in Ireland
Fleming Island
The University of Chicago
Northwestern University
National Institutes of Health

Research output: Contribution to journal › Article › peer-review

745 Scopus citations

Abstract

Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several cancers. While these immunotherapies have improved patient outcomes in many clinical settings, they bring accompanying risks of toxicity, specifically immune-related adverse events (irAEs). There is a need for clear, effective guidelines for the management of irAEs during ICI treatment, motivating the Society for Immunotherapy of Cancer (SITC) to convene an expert panel to develop a clinical practice guideline. The panel discussed the recognition and management of single and combination ICI irAEs and ultimately developed evidence- and consensus-based recommendations to assist medical professionals in clinical decision-making and to improve outcomes for patients.

Original language	English
Article number	e002435
Journal	Journal for ImmunoTherapy of Cancer
Volume	9
Issue number	6
DOIs	https://doi.org/10.1136/jitc-2021-002435
State	Published - Jun 25 2021

Keywords

Antineoplastic protocols
Guidelines as topic
Immunotherapy

Access to Document

10.1136/jitc-2021-002435

Cite this

Brahmer, J. R., Abu-Sbeih, H., Ascierto, P. A., Brufsky, J., Cappelli, L. C., Cortazar, F. B., Gerber, D. E., Hamad, L., Hansen, E., Johnson, D. B., Lacouture, M. E., Masters, G. A., Naidoo, J., Nanni, M., Perales, M. A., Puzanov, I., Santomasso, B. D., Shanbhag, S. P., Sharma, R., ... Ernstoff, M. S. (2021). Society for immunotherapy of cancer (sitc) clinical practice guideline on immune checkpoint inhibitor-related adverse events. Journal for ImmunoTherapy of Cancer, 9(6), Article e002435. https://doi.org/10.1136/jitc-2021-002435

@article{5ae80e34d1ab4866bb3f6abe8bd5d61a,

title = "Society for immunotherapy of cancer (sitc) clinical practice guideline on immune checkpoint inhibitor-related adverse events",

abstract = "Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several cancers. While these immunotherapies have improved patient outcomes in many clinical settings, they bring accompanying risks of toxicity, specifically immune-related adverse events (irAEs). There is a need for clear, effective guidelines for the management of irAEs during ICI treatment, motivating the Society for Immunotherapy of Cancer (SITC) to convene an expert panel to develop a clinical practice guideline. The panel discussed the recognition and management of single and combination ICI irAEs and ultimately developed evidence- and consensus-based recommendations to assist medical professionals in clinical decision-making and to improve outcomes for patients.",

keywords = "Antineoplastic protocols, Guidelines as topic, Immunotherapy",

author = "Brahmer, \{Julie R.\} and Hamzah Abu-Sbeih and Ascierto, \{Paolo Antonio\} and Jill Brufsky and Cappelli, \{Laura C.\} and Cortazar, \{Frank B.\} and Gerber, \{David E.\} and Lamya Hamad and Eric Hansen and Johnson, \{Douglas B.\} and Lacouture, \{Mario E.\} and Masters, \{Gregory A.\} and Jarushka Naidoo and Michele Nanni and Perales, \{Miguel Angel\} and Igor Puzanov and Santomasso, \{Bianca D.\} and Shanbhag, \{Satish P.\} and Rajeev Sharma and Dimitra Skondra and Sosman, \{Jeffrey A.\} and Michelle Turner and Ernstoff, \{Marc S.\}",

note = "Publisher Copyright: {\textcopyright} Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.",

year = "2021",

month = jun,

day = "25",

doi = "10.1136/jitc-2021-002435",

language = "English",

volume = "9",

journal = "Journal for ImmunoTherapy of Cancer",

issn = "2051-1426",

publisher = "BMJ Publishing Group",

number = "6",

}

Brahmer, JR, Abu-Sbeih, H, Ascierto, PA, Brufsky, J, Cappelli, LC, Cortazar, FB, Gerber, DE, Hamad, L, Hansen, E, Johnson, DB, Lacouture, ME, Masters, GA, Naidoo, J, Nanni, M, Perales, MA, Puzanov, I, Santomasso, BD, Shanbhag, SP, Sharma, R, Skondra, D, Sosman, JA, Turner, M & Ernstoff, MS 2021, 'Society for immunotherapy of cancer (sitc) clinical practice guideline on immune checkpoint inhibitor-related adverse events', Journal for ImmunoTherapy of Cancer, vol. 9, no. 6, e002435. https://doi.org/10.1136/jitc-2021-002435

TY - JOUR

T1 - Society for immunotherapy of cancer (sitc) clinical practice guideline on immune checkpoint inhibitor-related adverse events

AU - Brahmer, Julie R.

AU - Abu-Sbeih, Hamzah

AU - Ascierto, Paolo Antonio

AU - Brufsky, Jill

AU - Cappelli, Laura C.

AU - Cortazar, Frank B.

AU - Gerber, David E.

AU - Hamad, Lamya

AU - Hansen, Eric

AU - Johnson, Douglas B.

AU - Lacouture, Mario E.

AU - Masters, Gregory A.

AU - Naidoo, Jarushka

AU - Nanni, Michele

AU - Perales, Miguel Angel

AU - Puzanov, Igor

AU - Santomasso, Bianca D.

AU - Shanbhag, Satish P.

AU - Sharma, Rajeev

AU - Skondra, Dimitra

AU - Sosman, Jeffrey A.

AU - Turner, Michelle

AU - Ernstoff, Marc S.

PY - 2021/6/25

Y1 - 2021/6/25

N2 - Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several cancers. While these immunotherapies have improved patient outcomes in many clinical settings, they bring accompanying risks of toxicity, specifically immune-related adverse events (irAEs). There is a need for clear, effective guidelines for the management of irAEs during ICI treatment, motivating the Society for Immunotherapy of Cancer (SITC) to convene an expert panel to develop a clinical practice guideline. The panel discussed the recognition and management of single and combination ICI irAEs and ultimately developed evidence- and consensus-based recommendations to assist medical professionals in clinical decision-making and to improve outcomes for patients.

AB - Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several cancers. While these immunotherapies have improved patient outcomes in many clinical settings, they bring accompanying risks of toxicity, specifically immune-related adverse events (irAEs). There is a need for clear, effective guidelines for the management of irAEs during ICI treatment, motivating the Society for Immunotherapy of Cancer (SITC) to convene an expert panel to develop a clinical practice guideline. The panel discussed the recognition and management of single and combination ICI irAEs and ultimately developed evidence- and consensus-based recommendations to assist medical professionals in clinical decision-making and to improve outcomes for patients.

KW - Antineoplastic protocols

KW - Guidelines as topic

KW - Immunotherapy

UR - https://www.scopus.com/pages/publications/85108885057

U2 - 10.1136/jitc-2021-002435

DO - 10.1136/jitc-2021-002435

M3 - Article

C2 - 34172516

AN - SCOPUS:85108885057

SN - 2051-1426

VL - 9

JO - Journal for ImmunoTherapy of Cancer

JF - Journal for ImmunoTherapy of Cancer

IS - 6

M1 - e002435

ER -

Society for immunotherapy of cancer (sitc) clinical practice guideline on immune checkpoint inhibitor-related adverse events

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this